It is made available under a CC-BY-NC-ND 4.0 International license .

1	A distinct T cell receptor signature associates with cardiac outcome in myocardial	
2	infarction patients	
3	Kenz Le Gouge* <sup>1</sup> , DiyaaElDin Ashour* <sup>2,3</sup> , Margarete Heinrichs** <sup>2,3</sup> , Paul Stys** <sup>1</sup> , Pierre	
4	Barennes** <sup>1</sup> , Verena Stangl <sup>4</sup> , Lavinia Rech <sup>5</sup> , Gerald Hoefler <sup>4</sup> , Karl Kashofer <sup>4</sup> , Tobias	
5	Gassenmaier <sup>6</sup> , Valerie Boivin-Jahns <sup>7</sup> , Roland Jahns <sup>8</sup> , Ulrich Hofmann <sup>2,3</sup> , Dominik Schmitt <sup>2</sup> ,	
6	Anna Frey <sup>2,3</sup> , Stefan Störk <sup>2,3</sup> , Stefan Frantz <sup>2,3</sup> , Peter P. Rainer <sup>5,9,10§</sup> , Gustavo Campos	
7	Ramos <sup>2,3§</sup> , Encarnita Mariotti-Ferrandiz <sup>1,11§</sup>	
8		
9	<sup>1</sup> Sorbonne Université, INSERM, UMRS959, Immunology-Immunopathology-Immunotherapy (i3),	
10	Paris, France	
11	<sup>2</sup> Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany	
12	<sup>3</sup> Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany	
13	<sup>4</sup> Diagnostic and Research Institute of Pathology, Medical University of Graz	
14	<sup>5</sup> Division of Cardiology, Medical University of Graz, Graz, Austria	
15	<sup>6</sup> Department of Diagnostic and interventional Radiology, University Hospital of Würzburg, Germany	
16	<sup>7</sup> Institute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany.	
17	<sup>8</sup> Interdisciplinary Bank of Biomaterials and Data Würzburg (IBDW), University Hospital of Würzburg,	
18	Würzburg, Germany.	
19	<sup>9</sup> BioTechMed Graz, Graz, Austria	
20	<sup>10</sup> St. Johann in Tirol General Hospital, St. Johann in Tirol, Austria	
21	<sup>11</sup> Institut Universitaire de France (IUF)	
22		
23	* Equally contributed	
24	** Equally contributed	
25	_	
26	§ Corresponding authors	
27 28 29 30 31 32 33 34 35 36 37	CardioScience Lab 39 Division of Cardiology 40 Medical University of Graz 41 A-8036 Graz, Austria 42 Phone: +43 316 385 12544 43 Fax: +43 316 385 13733 44 Email: 45 peter.rainer@medunigraz.at 46 47 48	<ul> <li>University Hospital Würzbürg, Immunopathology-</li> <li>Department of Internal Medidiae Immunotherapy lab</li> <li>I, 54</li> <li>Am Schwarzenberg 15, Hātās 83 boulevard de l'Hôpital</li> <li>A15 56</li> <li>D-97078 Würzburg, Germany57</li> <li>France</li> <li>Phone: +49 931 201 46477 58</li> <li>Fax: +49 931 201 46485 59</li> <li>Email: Ramos_G@ukw.de</li> <li>60</li> <li>encarnita.mariotti@sorbonne-</li> <li>universite.fr</li> <li>62</li> </ul>
63 64	<b>Keywords:</b> Myocardial infarction, ejection fraction, T cell, TCR, lymphocytes.	
65	Article type: Rapid communication	

66

It is made available under a CC-BY-NC-ND 4.0 International license .

## 67 List of non-standard abbreviations:

MRI: cardiac magnetic resonance imaging, ESV: end-systolic volume, EDV: end-diastolic volume
FUP: follow-up visit, HF: Heart failure, LVEF: left-ventricular ejection fraction, MI: myocardial
infarction, STEMI: ST-elevation myocardial infarction, TCR: T cell receptor, TRA: T cell receptor,
alpha chain, TRB: T cell receptor, beta chain

72

## 73 Abstract

74 Myocardial infarction (MI) is associated with an inflammatory process mainly attributed to 75 innate immune components. Very recently, the role of T-cells in both inflammation and 76 healing has been suggested through various human and mouse studies. Previous studies 77 showed that CD4+ and CD8+ T cells affect post-MI repair but did not investigate how to 78 leverage T cell biology to predict post-MI outcomes in patients. For instance, the antigenic 79 trigger of T-cells is still unknown in human. Indeed, others and we identified T-cell specific 80 for myosin infiltrating the myocardium in mouse models of MI, recent studies identified 81 expanded clones in human myocardium, altogether suggesting a tissue-specific T-cell 82 activation. However, it is still unclear how acute post-MI immune responses shape long-term 83 cardiac functional outcomes in individual patients. In this study, we analyzed the role of T-84 cell in predicting post-MI repair by analyzing the T-cell receptor (TCR) repertoire. Indeed, the 85 TCR repertoire is now considered as a marker of the clinical status of individuals. Previous 86 studies in infectious but also autoimmune contexts showed the potential of the TCR 87 repertoire to predict the disease. Therefore, assessing the dynamic changes in global TCR 88 repertoires may provide valuable information about the antigen-specific immune responses 89 underlying post-MI healing. In our study, we carefully selected patients that suffered from MI 90 on a prospective cohort. The TCR repertoire has been analyzed by next generation 91 sequencing at the index hospitalization with the aim to identify features predict of their 92 healing outcome assessed at 12 months post-MI. While no major variations have been found 93 in diversity of TCR gene usage, we identified unique TCR signatures predicting one-year 94 cardiac functional outcomes. Our result enables early immune-based risk stratification of MI 95 patients and calls for larger studies to develop novel predictive biomarkers and possibly new 96 therapeutics.

97

## 98 Main text

99 Inflammatory processes govern post-myocardial infarction (MI) healing and remodelling. Yet, 100 we cannot predict how acute post-MI immune responses shape long-term cardiac functional 101 outcomes in individual patients. Previous studies showed that CD4<sup>+</sup> and CD8<sup>+</sup> T cells are 102 key actors of the post-MI repair regulation(1, 2) but did not investigate how they could be

It is made available under a CC-BY-NC-ND 4.0 International license .

used as predictors of the cardiac outcome. Here, we sought to identify T cell receptor (TCR)
signatures predicting cardiac functional outcomes in a well-characterized MI patient
cohort(3).

106 TCRs are heterodimeric antigen-specific receptors expressed by T cells, generated through 107 somatic recombination of multiple gene segments in a process that generates a potential 108 repertoire of 10<sup>19</sup> unique receptors(4). Thus, we hypothesised that analysing TCR 109 repertoires in patients after MI could provide valuable information on the individual 110 immunological status underlying post-MI healing outcomes.

111 First, we selected acute ST-elevation MI-patients from the ETiCS cohort (Etiology, Titre-112 Course, and effect of autoimmunity on **S**urvival study(3), Würzburg arm) exhibiting reduced 113 left ventricular ejection fraction (LVEF) assessed by cardiac magnetic resonance (cMRI) on 114 day 4 post-MI (LVEF <50%, 54/150 patients). Amongst those, we further selected patients 115 with complete serial cMRI scans at baseline and 12 months of follow-up (FU) (38/54 116 patients) (Figure 1A). Next, we stratified these patients into "good" versus "poor" healers 117 based on a priori defined cMRI criteria(5)). In brief, patients showing a  $\Delta$ LVEF <13% 118 between baseline and follow-up (FUP) were defined as "poor healers" (25/38), whereas 119 those showing greater improvement ( $\Delta LVEF > 13\%$ ) were considered "good healers" (13/38) 120 (**Figure 1B**). In addition to lower  $\triangle$ LVEF values (P<0.0001), poor healers had significantly 121 greater  $\Delta$  end-systolic volumes (ESV) (P<0.0001), whereas  $\Delta$  end-diastolic volumes (EDV) 122 did not differ. Age, BMI, infarct size, and routine blood biomarkers were similar in poor and 123 good healers at baseline (Figure 1B). After defining groups of MI-patients with diverging 124 healing phenotypes, we extracted RNA of cryopreserved whole blood samples that were 125 collected at hospital admission from all 25 poor and 13 good healers (Nucleospin RNA blood 126 kit, Macherey-Nagel, Düren, Germany). Due to technical limitations inherent to the 127 processing of archived biomaterial, we obtained RNA with sufficient quality from 19 poor and 128 9 good healers, which were then used for RT-PCR, amplification of TCR alpha and beta 129 chains (TRA and TRB respectively), library preparation and sequencing(6).

To evaluate potential global changes in the TCR repertoires found in blood sampled at baseline, we first measured the diversity of TCRs in each group by computing the Shannon entropy and the gene usage frequency (**Figure 1C-D**), two canonical measures of immune repertoire diversity(7). These basic analyses did not reveal any significant differences between groups. We then hypothesised that distinct TCR repertoire composition may explain healing outcomes. Thus, we devised a refined strategy to identify a set of TCRs that effectively differentiates between cardiac functional outcomes (**Figure 1E**). Accordingly,

It is made available under a CC-BY-NC-ND 4.0 International license .

137 using statistical modelling from Pogorely et al.(8) (Figure 1E, panel 1), we computed the 138 probability of each TCR being present in the dataset (Pdata) and identified TCRs that were 139 statistically enriched compared to their expected generation (Pgen). Additionally, we 140 searched for TCRs that were differentially represented between good and bad healers(9) 141 (Figure 1E, panel 2). Finally, we selected TCRs that met both criteria: being more 142 represented in one group than the other and having a statistically higher probability of being 143 present in the dataset than expected (Figure 1E, panel 3). As a result, we discovered a 144 signature of 348 unique TCRs (Figure 1F). Hierarchical clustering based on the 145 presence/absence of this signature allowed a separation of good from poor healers (cluster 146 purity = 0.93). Interestingly, this signature comprising 237 unique TRA and 111 unique TRB 147 was primarily present among the good rather than the poor healers. We then assessed the 148 relevance of the signature by comparing its cumulative frequency in the ETiCS patients 149 versus a group of healthy subjects (n = 27). Figure H shows that the cumulative frequency 150 of the signature is significantly higher in good healers when compared with poor healers and 151 healthy volunteers (p<0.001 for both TRA and TRB chains). Moreover, the TCR signature 152 was more enriched in healthy subjects when compared with poor healers (p<0.001 for TRA 153 and p<0.01 for TRB), suggesting that the clones found in the signature are specifically 154 depleted in MI patients with poor cardiac functional recovery (Figure 1G).

155 In summary, we identified a distinct TCR signature associated with cMRI-assessed post-MI 156 cardiac healing outcomes. Specifically, we found that MI-patients showing a substantial post-157 MI LVEF improvement were enriched for a set of 348 unique TCRs in the peripheral blood 158 already at baseline (hospitalization). These exploratory findings provide clinical evidence that 159 the individual TCR profile at early stages post-MI contributes to long-term healing outcomes 160 in humans. This supports the notion that modulation of T cell responses may eventually help 161 to improve post-MI remodelling(10) and further confirms that the circulating T cell 162 compartment is impacted by the ongoing cardiac repair. Moreover, the present findings 163 provide a compelling example on the value of immune-based diagnostics in cardiology. Still, 164 our study has some important limitations. First, it was a rather small - though well stratified 165 and characterized - retrospective patient collective. Moreover, since we analysed 166 cryopreserved whole blood samples, we were unable to phenotype T cell subsets that might 167 have accounted for the identified TCR signature. Furthermore, as it is currently not possible 168 to infer which antigens are recognised by the TCRs comprised in this distinct signature, the 169 mechanisms underlying their association with the cardiac functional outcomes remain 170 unknown. Still, our findings underline the potential predictive value of TCR repertoire 171 analyses in MI and might encourage further mechanistic investigations and confirmation in 172 larger patient cohorts.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 173

174 Author contribution: RJ, VJ, DS, AA, SS recruited the patients for this study and 175 coordinated the clinical study; TG analysed the cMRI images, MH, DA, LV, VS, PPR and 176 GCR retrospectively stratified and selected samples; DA, KLG, PS, PB, and EMF processed 177 the RNA samples, developed bioinformatic tools and analysed the TCR-seq data. DA, MH, 178 KLG, GH, UH, SF, PPR, EMF, GCR made substantial contributions to the conception and 179 design of the present work. KLG, DA, PPR, EMF, and GCR drafted the manuscript. PPR, 180 EMF, and GCR supervised this study. All co-authors critically revised it, made significant 181 intellectual contribution, and approved the manuscript in its final version to be published. 182 183 Acknowledgements: 184 This work benefited from equipment and services from the iGenSeq core facility at Institut du 185 Cerveau (ICM, Paris, France) for all the TCR data production. 186 187 Data availability statement 188 The anonymised TCR-seq raw files can be made available upon reasonable request. 189 190 **Conflict of interest statement** 191 The authors declare no conflict of interest. 192 193 **Funding statement** 194 This work was supported by the European Research Area Network-Cardiovascular 195 Diseases [ERANET-CVD JCT2018, AIR-MI Consortium to GCR (01KL1902), PPR (4168-B) 196 and EMF (ANR-18-ECVD-0001)]. The ETICS study was supported by the 197 Bundesministerium für Bildung und Forschung (BMBF), grant "Molecular Diagnostics" FKZ 198 01ES0901 and FKZ 01ES0802 (to V.B.-J. and R.J.). SF work was supported by BMBF ( 199 01EO1004). KLG doctoral fellowship was supported by ERANET-CVD JCT2018 (ANR-18-200 ECVD-0001) and additional support from Sorbonne Université. EMF work was supported by 201 the iReceptorPlus (H2020 Research and Innovation Programme 825821) and SirocCo 202 (ANR-21-CO12-0005-01) grants and the Institut Universitaire de France. GCR is supported 203 by the Interdisciplinary Centre for Clinical Research Würzburg [E-354]. GCR, UH, SF and AF 204 received funding from the German Research foundation (through the Collaborative Research 205 Centre "Cardio-Immune interfaces" SFB1525, grant number 453989101). 206

206


207 References

It is made available under a CC-BY-NC-ND 4.0 International license .

- 208 1. Forte E, et al. Cross-Priming Dendritic Cells Exacerbate Immunopathology After Ischemic
- Tissue Damage in the Heart. *Circulation*. 2021;143(8):821–836.
- 210 2. Rieckmann M, et al. Myocardial infarction triggers cardioprotective antigen-specific T
- helper cell responses. Journal of Clinical Investigation. 2019;129(11):4922–4936.
- 3. Deubner N, et al. Cardiac beta1-adrenoceptor autoantibodies in human heart disease:
- rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study. Eur J Heart
- 214 Fail. 2010;12(7):753–762.
- 4. Bradley P, Thomas PG. Using T Cell Receptor Repertoires to Understand the Principles
- of Adaptive Immune Recognition. *Annu Rev Immunol.* 2019;37(1):547–570.
- 5. Bulluck H, et al. Defining left ventricular remodeling following acute ST-segment elevation
- 218 myocardial infarction using cardiovascular magnetic resonance. *Journal of Cardiovascular*
- 219 *Magnetic Resonance*. 2017;19(1):26.
- 220 6. Barennes P, et al. Benchmarking of T cell receptor repertoire profiling methods reveals
- large systematic biases. *Nat Biotechnol.* 2021;39(2):236–245.
- 222 7. Six A, et al. The Past, Present, and Future of Immune Repertoire Biology The Rise of
- 223 Next-Generation Repertoire Analysis. Front Immunol. 2013;4.
- 224 https://doi.org/10.3389/fimmu.2013.00413.
- 8. Pogorelyy MV, et al. Method for identification of condition-associated public antigen
- receptor sequences. *eLife*. 2018;7:e33050.
- 9. Emerson RO, et al. Immunosequencing identifies signatures of cytomegalovirus exposure
- history and HLA-mediated effects on the T cell repertoire. *Nat Genet*. 2017;49(5):659–665.
- 229 10. Zhao TX, et al. Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart
- 230 Disease. *NEJM Evidence*. 2022;1(1):EVIDoa2100009.

It is made available under a CC-BY-NC-ND 4.0 International license .

It is made available under a CC-BY-NC-ND 4.0 International license .



It is made available under a CC-BY-NC-ND 4.0 International license .

233 Figure 1: A distinct T cell receptor signature associates with cardiac functional 234 outcomes in myocardial infarction patients. (A) Patient selection and stratification into 235 good vs poor healers based on cMRI findings. The number of patients is indicated within the 236 boxes (B) cMRI findings, including LVEF at baseline and FUP 12 months in good vs poor 237 healers,  $\Delta LVEF$  (%),  $\Delta ESV$  and  $\Delta EDV$  (mL), and distribution of confounding factors between 238 groups (BMI: body-mass index; LDH: lactate dehydrogenase; Time: time from pain to 239 intervention; LGE: infarct size assessed by late gadolinium enhancement, CRP: C-reactive 240 protein, WBC: white blood cell count; RBC: red blood cell count, Hgb: hemoglobin; Plat: 241 platelets count; NTproBNP; N-terminal pro-brain natriuretic peptide; Chol: cholesterol; Creat: 242 creatinine; SBP: systolic blood pressure; Alb: albumin. Values are expressed as fold change 243 from the average levels found in the "good healer" group). (C) Shannon index based on 244 clone counts from aligned TCR samples for the alpha and beta chain. P-value was 245 computed using Wilcoxon U-test. (D) Non-metric dimensional scaling of the TRB variable 246 (TRBV) and joining (TRBJ) gene usage frequencies. (E) Strategy used to identify 247 Complementarity-determining region 3 (CDR3, antigen-binding domain) signature. (F) 248 Heatmap of the 348 CDR3 signature found in patients. CDR3, by column, were clustered 249 independently by chain. (G) Sample's cumulative frequencies (in %) of the CDR3 from the 250 signature. Healthy volunteers are depicted in yellow.